Mizuho Securities Starts TCR2 Therapeutics (TCRR) at Buy

Mizuho Securities analyst Mara Goldstein initiates coverage on TCR2 Therapeutics (NASDAQ: TCRR) with a Buy rating and a price target of $33.00.

The analyst commented, "We initiate coverage of TCRR with a BUY rating and an $33 PT based on our view that the company's T-cell receptor fusion construct (TRuC)-T platform can drive substantial value creation as additional validating events occur. TCRR has shown early signs of technological validation in mesothelin (MSLN)-expressing solid tumors, and an updated dataset is expected in 2H20. The technology, in our view, combines advantageous elements of CARs and TCRs that address larger markets than each modality on its own, which raises the value of the pipeline."

For an analyst ratings summary and ratings history on TCR2 Therapeutics click here. For more ratings news on TCR2 Therapeutics click here.

Shares of TCR2 Therapeutics closed at $19.82 yesterday.

You May Also Be Interested In

• BofA Securities Resumes American Eagle Outfitters (AEO) at Underperform
• UBS Reiterates Buy Rating on NVIDIA (NVDA), Expects Q2 Revenue Beat
• Powell Industries (POWL) PT Lowered to $235 at Cantor Fitzgerald